Mrs
Dr
Miss
Ms
Prof
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/577424
Antiparasitics in the Animal Health Industry: 2007 edition
Description:
“Globally, this segment had a value of approximately $5.1 billion in 2006, making it the single most valuable sector within the animal health market… and therefore probably the most competitive.” This report analyzes the structure, recent development and growth prospects of the world market for antiparasitics and profiles several key national markets that generate two-thirds of global sales in the sector between them.
Key coverage
- Assess the most significant parasites affecting companion and food producing animals, and the impact they have on their host.
- Examine the methods used to treat or control the parasites with all major product categories discussed in detail including mode of action and spectrum of activity.
- Analyse company profiles for both originator companies with major interests in the sector as well as generic manufacturers to help you identify competitors.
- Identify the size and structure of the world market, its recent developments and future growth prospects to help you plan your future strategy.
Market data
- The ultimate guide to the animal health industry and its major players is updated and improved for 2007. With 26 company profiles included to further enhance your competitor intelligence
- In-depth company profiles are given for the top 12 animal health companies and a further 14 second tier companies.
Key findings
- The continuous growth of the whole segment in recent years has mostly been due to the new products commercialised in the companion animal ectoparasiticides segment.
- However, sales in other parts of the market have been affected by growing generic penetration.
- The development of vaccines against parasites is still a subject of high interest in both the academic and commercial sectors. However outside the coccidiosis sector these have generated fairly modest revenues to date.
- The major players in the sector are working on the development of novel antiparasitics, and some new products are expected to reach the market in the next 5 years.
Chapters
Major Livestock and Companion Animal Parasites
Antiparasitic Products
The Market for Antiparasitic Products
Company Profiles - for originator companies and generic manufacturers
Who should read this report?
Companies that are involved in the development, manufacture and sale of animal health products either as originator companies or generic manufacturers.
Key coverage
- Assess the most significant parasites affecting companion and food producing animals, and the impact they have on their host.
- Examine the methods used to treat or control the parasites with all major product categories discussed in detail including mode of action and spectrum of activity.
- Analyse company profiles for both originator companies with major interests in the sector as well as generic manufacturers to help you identify competitors.
- Identify the size and structure of the world market, its recent developments and future growth prospects to help you plan your future strategy.
Market data
- The ultimate guide to the animal health industry and its major players is updated and improved for 2007. With 26 company profiles included to further enhance your competitor intelligence
- In-depth company profiles are given for the top 12 animal health companies and a further 14 second tier companies.
Key findings
- The continuous growth of the whole segment in recent years has mostly been due to the new products commercialised in the companion animal ectoparasiticides segment.
- However, sales in other parts of the market have been affected by growing generic penetration.
- The development of vaccines against parasites is still a subject of high interest in both the academic and commercial sectors. However outside the coccidiosis sector these have generated fairly modest revenues to date.
- The major players in the sector are working on the development of novel antiparasitics, and some new products are expected to reach the market in the next 5 years.
Chapters
Major Livestock and Companion Animal Parasites
Antiparasitic Products
The Market for Antiparasitic Products
Company Profiles - for originator companies and generic manufacturers
Who should read this report?
Companies that are involved in the development, manufacture and sale of animal health products either as originator companies or generic manufacturers.
Contents:
CHAPTER 1 MAJOR LIVESTOCK AND COMPANION ANIMAL PARASITES 11
1.1 Cattle parasites 11
1.1.1 Endoparasites 11
- Gastrointestinal nematodes 12
- Tapeworms 13
- Lungworms 13
- Liver fluke 14
- Protozoa 14
- Treatment and control of endoparasites 14
1.1.2 Ectoparasites 15
- Flies 16
- Lice 18
- Mites 18
- Ticks 18
- Treatment and control 19
1.2 Sheep parasites 20
1.2.1 Endoparasites 20
- Gastrointestinal nematodes 21
- Tapeworms 21
- Lungworms 21
- Liver flukes 21
- Protozoa 22
- Treatment and control 22
1.2.2 Ectoparasites 22
- Flies 22
- Mites 24
- Lice 24
- Ticks 24
- Treatment and control 24
1.3 Pig parasites 25
1.3.1 Endoparasites 25
- Gastrointestinal nematodes 25
- Protozoa 26
- Treatment and control 26
1.3.2 Ectoparasites 27
- Treatment and control 27
1.4 Horse parasites 27
1.4.1 Endoparasites 27
- Treatment and control 29
1.4.2 Ectoparasites 29
- Treatment and control 30
1.5 Small animal parasites 30
1.5.1 Endoparasites 31
- Gastrointestinal worms 31
- Tapeworms 32
- Heartworm 32
- Protozoa 33
- Treatment and control 33
1.5.2 Ectoparasites 34
- Fleas 34
- Ticks 34
- Mites 35
- Treatment and control 35
CHAPTER 2 ANTIPARASITIC PRODUCTS 37
2.1 Endoparasiticides 38
2.1.1 Imidazothiazoles 38
2.1.2 Benzimidazoles 39
2.1.3 Tetrahydropyrimidines 40
2.1.4 Macrocyclic lactones 41
2.1.5 Other endoparasiticides 42
2.2 Endectocides 43
2.2.1 Avermectins 44
- Ivermectin 44
- Abamectin 45
- Eprinomectin 45
- Doramectin 45
- Selamectin 46
- Emamectin 46
2.2.2 Milbemycins 46
- Milbemycin oxime 46
- Moxidectin 47
2.2.3 Quasi-endectocides 47
2.3 Ectoparasiticides 47
2.3.1 Carbamates 48
2.3.2 Insect growth regulators 48
- Chitin synthesis inhibitors 48
- Juvenile hormone mimics 50
- Other insect growth regulators 50
2.3.3 Macrocyclic lactones 50
2.3.4 Nicotinoids 51
2.3.5 Organophosphates 51
2.3.6 Pyrazoles 52
2.3.7 Pyrethrins and synthetic pyrethroids 53
2.3.8 Spinosyns 54
2.3.9 Others 54
2.3.10 Combination products 55
2.4 Parasite vaccines 55
2.4.1 Parasitic bronchitis vaccine 55
2.4.2 Cattle tick vaccine 55
2.4.3 Giardiasis vaccine 56
2.4.4 Toxoplasmosis vaccine 56
2.4.5 Neosporosis vaccine 56
2.5 Antiparasitic research 56
2.5.1 Endoparasiticide and endectocide research 57
2.5.2 Ectoparasiticide research 58
2.5.3 Parasite vaccine research 59
2.5.4 Alternative approaches to parasite control 61
CHAPTER 3 THE MARKET FOR ANTIPARASITIC PRODUCTS 63
3.1 The world market for animal health products 63
3.1.1 Structure of the world market by product category 63
3.2 The world market for antiparasitic products 64
3.2.1 Antiparasitic product sectors 65
3.2.2 Company involvement 66
3.2.3 Leading country markets 66
3.2.4 Market prospects 67
3.3 National market profiles 69
3.3.1 Australia 69
3.3.1.1 Market size and recent growth 69
3.3.1.2 Market structure 70
3.3.1.3 Structure and development of the Australian antiparasitics market 70
- Large animal antiparasitics 72
- Small animal antiparasitics 73
3.3.1.4 Antiparasitic market prospects 73
- Market forecast 74
3.3.2 Brazil 75
3.3.2.1 Market size and recent growth 75
3.3.2.2 Market structure 76
3.3.2.3 Structure and development of the Brazilian antiparasitics market 76
- Anthelmintics 77
- Ectoparasiticides 77
- Endectocides 78
3.3.2.4 Antiparasitic market prospects 78
- Market forecast 80
3.3.3 France 80
3.3.3.1 Market size and recent growth 80
3.3.3.2 Market structure 81
3.3.3.3 Structure and development of the French antiparasitics market 81
- Anthelmintics 82
- Endectocides 82
- Insecticides/ectoparasiticides 83
3.3.3.4 Antiparasitic market prospects 83
- Market forecast 84
3.3.4 Japan 85
3.3.4.1 Market size and recent growth 85
3.3.4.2 Market structure 85
3.3.4.3 Structure and development of the Japanese antiparasitics market 86
- Anthelmintics 87
- Endectocides 87
- Ectoparasiticides 87
3.3.4.4 Antiparasitic market prospects 88
- Market forecast 89
3.3.5 UK 90
3.3.5.1 Market size and recent growth 90
3.3.5.2 Market structure 90
3.3.5.3 Structure and development of the UK antiparasitics market 91
- Anthelmintics 92
- Ectoparasiticides 92
- Endectocides 93
3.3.5.4 Antiparasitic growth prospects 93
- Market forecast 94
3.3.6 USA 95
3.3.6.1 Market size and recent growth 95
3.3.6.2 Market structure 95
3.3.6.3 Size and structure of the US antiparasitics market 96
- Pet flea/tick treatments 97
- Heartworm preventatives 97
- Cattle wormers 98
- Equine anthelmintics 99
- Others 99
3.3.6.4 Antiparasitic market prospects 100
- Market forecast 101
3.3.7 Other significant markets 101
CHAPTER 4 COMPANY PROFILES 103
4.1 Leading originator companies 103
4.1.1 Bayer 104
4.1.1.1 Company background 104
4.1.1.2 Antiparasitics business 105
4.1.1.3 Major antiparasitic products 106
- Imidacloprid 106
- Other ectoparasiticides 107
- Anthelmintics and endectocides 107
4.1.1.4 Antiparasitic research 108
4.1.2 Fort Dodge 109
4.1.2.1 Company background 109
4.1.2.2 Antiparasitics business 109
4.1.2.3 Major antiparasitic products 110
- Moxidectin 110
- Other antiparasitics 111
4.1.2.4 Antiparasitic research 112
4.1.3 Intervet 112
4.1.3.1 Company background 112
4.1.3.2 Antiparasitics business 113
4.1.3.3 Major antiparasitic products 113
- Fenbendazole 113
- Other anthelmintics and endectocides 114
- Ectoparasiticides 114
- Vaccines 114
4.1.3.4 Antiparasitic research 115
4.1.4 Merial 115
4.1.4.1 Company background 115
4.1.4.2 Antiparasitics business 116
4.1.4.3 Major antiparasitic products 116
- Fipronil 116
- Avermectins 117
- Others 119
4.1.4.4 Antiparasitic research 120
4.1.5 Novartis 121
4.1.5.1 Company background 121
4.1.5.2 Antiparasitics business 121
4.1.5.3 Major antiparasitic products 122
- Companion animal products 122
- Livestock products 124
- Premise and environmental parasite controls 124
4.1.5.4 Antiparasitic research 124
4.1.6 Pfizer 125
4.1.6.1 Company background 125
4.1.6.2 Antiparasitics business 125
4.1.6.3 Major antiparasitic products 126
- Doramectin 126
- Selamectin 127
- Others 127
4.1.6.4 Antiparasitic research 128
4.1.7 Schering-Plough 129
4.1.7.1 Company background 129
4.1.7.2 Antiparasitics business 129
4.1.7.3 Major antiparasitic products 130
- Ectoparasiticides 130
- Anthelmintics and endectocides 131
4.1.7.4 Antiparasitic research 131
4.2 Major generic companies 132
4.2.1 Ancare 133
4.2.1.1 Company background 133
4.2.1.2 Strategy 133
4.2.1.3 Product range 134
4.2.1.4 Recent launches 134
4.2.2 Farnam 135
4.2.2.1 Company background 135
4.2.2.2 Strategy 136
4.2.2.3 Product range 136
4.2.3 Norbrook 137
4.2.3.1 Company background 137
4.2.3.2 Strategy 138
4.2.3.3 Product range 138
4.2.4 Phoenix Scientific 140
4.2.4.1 Company background 140
4.2.4.2 Strategy 140
4.2.4.3 Product range 141
4.2.5 Virbac 142
4.2.5.1 Company background 142
4.2.5.2 Strategy 142
4.2.5.3 Product range 143
- Endectocides 143
- Others 143
1.1 Cattle parasites 11
1.1.1 Endoparasites 11
- Gastrointestinal nematodes 12
- Tapeworms 13
- Lungworms 13
- Liver fluke 14
- Protozoa 14
- Treatment and control of endoparasites 14
1.1.2 Ectoparasites 15
- Flies 16
- Lice 18
- Mites 18
- Ticks 18
- Treatment and control 19
1.2 Sheep parasites 20
1.2.1 Endoparasites 20
- Gastrointestinal nematodes 21
- Tapeworms 21
- Lungworms 21
- Liver flukes 21
- Protozoa 22
- Treatment and control 22
1.2.2 Ectoparasites 22
- Flies 22
- Mites 24
- Lice 24
- Ticks 24
- Treatment and control 24
1.3 Pig parasites 25
1.3.1 Endoparasites 25
- Gastrointestinal nematodes 25
- Protozoa 26
- Treatment and control 26
1.3.2 Ectoparasites 27
- Treatment and control 27
1.4 Horse parasites 27
1.4.1 Endoparasites 27
- Treatment and control 29
1.4.2 Ectoparasites 29
- Treatment and control 30
1.5 Small animal parasites 30
1.5.1 Endoparasites 31
- Gastrointestinal worms 31
- Tapeworms 32
- Heartworm 32
- Protozoa 33
- Treatment and control 33
1.5.2 Ectoparasites 34
- Fleas 34
- Ticks 34
- Mites 35
- Treatment and control 35
CHAPTER 2 ANTIPARASITIC PRODUCTS 37
2.1 Endoparasiticides 38
2.1.1 Imidazothiazoles 38
2.1.2 Benzimidazoles 39
2.1.3 Tetrahydropyrimidines 40
2.1.4 Macrocyclic lactones 41
2.1.5 Other endoparasiticides 42
2.2 Endectocides 43
2.2.1 Avermectins 44
- Ivermectin 44
- Abamectin 45
- Eprinomectin 45
- Doramectin 45
- Selamectin 46
- Emamectin 46
2.2.2 Milbemycins 46
- Milbemycin oxime 46
- Moxidectin 47
2.2.3 Quasi-endectocides 47
2.3 Ectoparasiticides 47
2.3.1 Carbamates 48
2.3.2 Insect growth regulators 48
- Chitin synthesis inhibitors 48
- Juvenile hormone mimics 50
- Other insect growth regulators 50
2.3.3 Macrocyclic lactones 50
2.3.4 Nicotinoids 51
2.3.5 Organophosphates 51
2.3.6 Pyrazoles 52
2.3.7 Pyrethrins and synthetic pyrethroids 53
2.3.8 Spinosyns 54
2.3.9 Others 54
2.3.10 Combination products 55
2.4 Parasite vaccines 55
2.4.1 Parasitic bronchitis vaccine 55
2.4.2 Cattle tick vaccine 55
2.4.3 Giardiasis vaccine 56
2.4.4 Toxoplasmosis vaccine 56
2.4.5 Neosporosis vaccine 56
2.5 Antiparasitic research 56
2.5.1 Endoparasiticide and endectocide research 57
2.5.2 Ectoparasiticide research 58
2.5.3 Parasite vaccine research 59
2.5.4 Alternative approaches to parasite control 61
CHAPTER 3 THE MARKET FOR ANTIPARASITIC PRODUCTS 63
3.1 The world market for animal health products 63
3.1.1 Structure of the world market by product category 63
3.2 The world market for antiparasitic products 64
3.2.1 Antiparasitic product sectors 65
3.2.2 Company involvement 66
3.2.3 Leading country markets 66
3.2.4 Market prospects 67
3.3 National market profiles 69
3.3.1 Australia 69
3.3.1.1 Market size and recent growth 69
3.3.1.2 Market structure 70
3.3.1.3 Structure and development of the Australian antiparasitics market 70
- Large animal antiparasitics 72
- Small animal antiparasitics 73
3.3.1.4 Antiparasitic market prospects 73
- Market forecast 74
3.3.2 Brazil 75
3.3.2.1 Market size and recent growth 75
3.3.2.2 Market structure 76
3.3.2.3 Structure and development of the Brazilian antiparasitics market 76
- Anthelmintics 77
- Ectoparasiticides 77
- Endectocides 78
3.3.2.4 Antiparasitic market prospects 78
- Market forecast 80
3.3.3 France 80
3.3.3.1 Market size and recent growth 80
3.3.3.2 Market structure 81
3.3.3.3 Structure and development of the French antiparasitics market 81
- Anthelmintics 82
- Endectocides 82
- Insecticides/ectoparasiticides 83
3.3.3.4 Antiparasitic market prospects 83
- Market forecast 84
3.3.4 Japan 85
3.3.4.1 Market size and recent growth 85
3.3.4.2 Market structure 85
3.3.4.3 Structure and development of the Japanese antiparasitics market 86
- Anthelmintics 87
- Endectocides 87
- Ectoparasiticides 87
3.3.4.4 Antiparasitic market prospects 88
- Market forecast 89
3.3.5 UK 90
3.3.5.1 Market size and recent growth 90
3.3.5.2 Market structure 90
3.3.5.3 Structure and development of the UK antiparasitics market 91
- Anthelmintics 92
- Ectoparasiticides 92
- Endectocides 93
3.3.5.4 Antiparasitic growth prospects 93
- Market forecast 94
3.3.6 USA 95
3.3.6.1 Market size and recent growth 95
3.3.6.2 Market structure 95
3.3.6.3 Size and structure of the US antiparasitics market 96
- Pet flea/tick treatments 97
- Heartworm preventatives 97
- Cattle wormers 98
- Equine anthelmintics 99
- Others 99
3.3.6.4 Antiparasitic market prospects 100
- Market forecast 101
3.3.7 Other significant markets 101
CHAPTER 4 COMPANY PROFILES 103
4.1 Leading originator companies 103
4.1.1 Bayer 104
4.1.1.1 Company background 104
4.1.1.2 Antiparasitics business 105
4.1.1.3 Major antiparasitic products 106
- Imidacloprid 106
- Other ectoparasiticides 107
- Anthelmintics and endectocides 107
4.1.1.4 Antiparasitic research 108
4.1.2 Fort Dodge 109
4.1.2.1 Company background 109
4.1.2.2 Antiparasitics business 109
4.1.2.3 Major antiparasitic products 110
- Moxidectin 110
- Other antiparasitics 111
4.1.2.4 Antiparasitic research 112
4.1.3 Intervet 112
4.1.3.1 Company background 112
4.1.3.2 Antiparasitics business 113
4.1.3.3 Major antiparasitic products 113
- Fenbendazole 113
- Other anthelmintics and endectocides 114
- Ectoparasiticides 114
- Vaccines 114
4.1.3.4 Antiparasitic research 115
4.1.4 Merial 115
4.1.4.1 Company background 115
4.1.4.2 Antiparasitics business 116
4.1.4.3 Major antiparasitic products 116
- Fipronil 116
- Avermectins 117
- Others 119
4.1.4.4 Antiparasitic research 120
4.1.5 Novartis 121
4.1.5.1 Company background 121
4.1.5.2 Antiparasitics business 121
4.1.5.3 Major antiparasitic products 122
- Companion animal products 122
- Livestock products 124
- Premise and environmental parasite controls 124
4.1.5.4 Antiparasitic research 124
4.1.6 Pfizer 125
4.1.6.1 Company background 125
4.1.6.2 Antiparasitics business 125
4.1.6.3 Major antiparasitic products 126
- Doramectin 126
- Selamectin 127
- Others 127
4.1.6.4 Antiparasitic research 128
4.1.7 Schering-Plough 129
4.1.7.1 Company background 129
4.1.7.2 Antiparasitics business 129
4.1.7.3 Major antiparasitic products 130
- Ectoparasiticides 130
- Anthelmintics and endectocides 131
4.1.7.4 Antiparasitic research 131
4.2 Major generic companies 132
4.2.1 Ancare 133
4.2.1.1 Company background 133
4.2.1.2 Strategy 133
4.2.1.3 Product range 134
4.2.1.4 Recent launches 134
4.2.2 Farnam 135
4.2.2.1 Company background 135
4.2.2.2 Strategy 136
4.2.2.3 Product range 136
4.2.3 Norbrook 137
4.2.3.1 Company background 137
4.2.3.2 Strategy 138
4.2.3.3 Product range 138
4.2.4 Phoenix Scientific 140
4.2.4.1 Company background 140
4.2.4.2 Strategy 140
4.2.4.3 Product range 141
4.2.5 Virbac 142
4.2.5.1 Company background 142
4.2.5.2 Strategy 142
4.2.5.3 Product range 143
- Endectocides 143
- Others 143
Contents:
Companion animals and all of the major livestock species are exposed to challenge from a broad range of parasites. Most compromise the health and wellbeing of animals directly, while some present broader risks by acting as vectors for other pathogens. In livestock, parasite infestations exert a major impact on levels of productivity and profitability. Losses inflicted on producers at a global level run to many billions of dollars (liver fluke infestation alone causes losses of an estimated $3 billion worldwide).
The main weapons available to farmers and companion animal owners in the fight against parasites are chemotherapeutic drugs which either kill parasite populations or prevent the development of immature parasites into adult forms. Demand for these products supports a global market worth almost $4.7 billion, making it the single most valuable sector of the animal health products market.
Chapter one of this report identifies the most significant parasites that affect major livestock and companion animal species, describes their impact on host animals and discusses the methods used to treat or control them. In chapter two, the products used to treat or control these parasites are discussed in more detail. The mode of action and spectrum of activity possessed by chemical classes and individual products is described, and examples from the class used widely in veterinary medicine are identified.
Parasites that survive the application of these products are those with a natural tendency to resistance against the active ingredient or class in question. Over time, this results in the development of resistant populations. Drugs from different chemical classes are used in rotation programmes to slow the development of resistance, but the efficacy of some major antiparasitic groups against certain parasite species has nevertheless declined significantly as a result of resistance. This is driving the search for new chemical classes, and has also encouraged continued efforts to develop alternative parasite control methods, including immunological approaches. This work is also described in chapter two.
Chapter three of the report analyses the structure, recent development and future growth prospects of the world market for antiparasitic drugs, and profiles six key national markets that, together, generate two-thirds of global sales in the sector. Like the market as a whole, the dollar value of the antiparasitics market has been inflated recently by the weakness of the US currency. Nevertheless, it has been a major source of growth in real terms over the past 10 years - due in large part to the impact of new products commercialised in the companion animal ectoparasiticides segment, where Merial’s market-leading Frontline brand now generates annual sales of almost $700 million.
While new products have boosted values in the companion animal ectoparasiticides segment, sales in other parts of the market have been affected by growing generic penetration of the market. Ivermectin has been the most popular target for generic manufacturers since Merial’s patents on the molecule began to expire in major developed markets towards the end of the 1990s. Patents on several other leading antiparasitic brands have also expired during the past five years, however, and generic penetration of the antiparasitics market is set to increase further through the remainder of this decade as exclusivity periods for a number of other key products reach an end.
With generic penetration expected to offset the impact of new drug launches in the sector, increases in market value will be dependent largely on broad economic conditions and the operating environment facing livestock producers in major markets. The further development of existing products, through the application of formulation and delivery technologies or the commercialisation of multi-ingredient treatments, will also help to bolster market values. Real growth across the antiparasitic sector as a whole will be limited in most major markets, however, and gains at global level are forecast at a modest 2.5% a year, with sales expected to total just under $5.3 billion in 2009.
Just as a relatively small number of major markets generate major shares of the global antiparasitic sales total, so the sector is also dominated by a handful of companies. Merial alone realises annual sales of more than $1.1 billion in the antiparasitics market, giving it a share in the sector of almost 25%, while seven leading companies are responsible together for approximately 62% of global antiparasitic product sales. Chapter four of the report profiles the businesses of those seven leaders, analysing the product ranges on which their current market positions are based, and identifying areas in which their respective R&D programmes are likely to yield new products during the next five years.
While substantial shares of the market are concentrated in the hands of a few market leaders, the antiparasitics sector is becoming increasingly crowded as patents on major products expire. The range of companies attempting to cash in on new generic opportunities is extremely broad, but a few specialist generic manufacturers have emerged as major players in the sector. In addition to profiles of the market leaders, chapter four includes an analysis of five major generic players that have had a significant impact in the antiparasitic market, discussing individual company strategies and identifying their main interests in the antiparasitic products sector.
The main weapons available to farmers and companion animal owners in the fight against parasites are chemotherapeutic drugs which either kill parasite populations or prevent the development of immature parasites into adult forms. Demand for these products supports a global market worth almost $4.7 billion, making it the single most valuable sector of the animal health products market.
Chapter one of this report identifies the most significant parasites that affect major livestock and companion animal species, describes their impact on host animals and discusses the methods used to treat or control them. In chapter two, the products used to treat or control these parasites are discussed in more detail. The mode of action and spectrum of activity possessed by chemical classes and individual products is described, and examples from the class used widely in veterinary medicine are identified.
Parasites that survive the application of these products are those with a natural tendency to resistance against the active ingredient or class in question. Over time, this results in the development of resistant populations. Drugs from different chemical classes are used in rotation programmes to slow the development of resistance, but the efficacy of some major antiparasitic groups against certain parasite species has nevertheless declined significantly as a result of resistance. This is driving the search for new chemical classes, and has also encouraged continued efforts to develop alternative parasite control methods, including immunological approaches. This work is also described in chapter two.
Chapter three of the report analyses the structure, recent development and future growth prospects of the world market for antiparasitic drugs, and profiles six key national markets that, together, generate two-thirds of global sales in the sector. Like the market as a whole, the dollar value of the antiparasitics market has been inflated recently by the weakness of the US currency. Nevertheless, it has been a major source of growth in real terms over the past 10 years - due in large part to the impact of new products commercialised in the companion animal ectoparasiticides segment, where Merial’s market-leading Frontline brand now generates annual sales of almost $700 million.
While new products have boosted values in the companion animal ectoparasiticides segment, sales in other parts of the market have been affected by growing generic penetration of the market. Ivermectin has been the most popular target for generic manufacturers since Merial’s patents on the molecule began to expire in major developed markets towards the end of the 1990s. Patents on several other leading antiparasitic brands have also expired during the past five years, however, and generic penetration of the antiparasitics market is set to increase further through the remainder of this decade as exclusivity periods for a number of other key products reach an end.
With generic penetration expected to offset the impact of new drug launches in the sector, increases in market value will be dependent largely on broad economic conditions and the operating environment facing livestock producers in major markets. The further development of existing products, through the application of formulation and delivery technologies or the commercialisation of multi-ingredient treatments, will also help to bolster market values. Real growth across the antiparasitic sector as a whole will be limited in most major markets, however, and gains at global level are forecast at a modest 2.5% a year, with sales expected to total just under $5.3 billion in 2009.
Just as a relatively small number of major markets generate major shares of the global antiparasitic sales total, so the sector is also dominated by a handful of companies. Merial alone realises annual sales of more than $1.1 billion in the antiparasitics market, giving it a share in the sector of almost 25%, while seven leading companies are responsible together for approximately 62% of global antiparasitic product sales. Chapter four of the report profiles the businesses of those seven leaders, analysing the product ranges on which their current market positions are based, and identifying areas in which their respective R&D programmes are likely to yield new products during the next five years.
While substantial shares of the market are concentrated in the hands of a few market leaders, the antiparasitics sector is becoming increasingly crowded as patents on major products expire. The range of companies attempting to cash in on new generic opportunities is extremely broad, but a few specialist generic manufacturers have emerged as major players in the sector. In addition to profiles of the market leaders, chapter four includes an analysis of five major generic players that have had a significant impact in the antiparasitic market, discussing individual company strategies and identifying their main interests in the antiparasitic products sector.
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1582661
Order by Fax - using the order form below
Order By Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Printed Thursday, May 23, 2013
5:14:48 PM
5:14:48 PM
Fax order form
To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
Product name
Antiparasitics in the Animal Health Industry: 2007 edition
Web Address
http://www.researchandmarkets.com/reports/577424
Office Code
OC8DIQSOLUWQQV
Report Formats
Please enter the quantity of the report format you require.
| Format | Quantity | Price | Electronic (PDF) - Single User |
|
EURO€ 1,064.00 |
|---|
Contact information
Please enter all the information below in block capitals.
Title:
Mr
Mrs
Dr
Miss
Ms
Prof
Mrs
Dr
Miss
Ms
Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Page 2 of 2
Printed Thursday, May 23, 2013
5:14:48 PM
5:14:48 PM
Payment information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
Pay by Check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Pay by Wire Transfer:
Please transfer funds to:
Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp